A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies (Q33357438)

26 July 2017

A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies (English)

1 reference

26 July 2017

phase II clinical trial

0 references

author name string

U Matulonis

1

1 reference

26 July 2017

S Campos

2

1 reference

26 July 2017

L Duska

3

1 reference

26 July 2017

A Fuller

4

1 reference

26 July 2017

R Berkowitz

5

1 reference

26 July 2017

S Gore

6

1 reference

26 July 2017

M Roche

7

1 reference

26 July 2017

T Colella

8

1 reference

26 July 2017

H Lee

9

1 reference

26 July 2017

M V Seiden

10

1 reference

26 July 2017

Gynecologic Oncology Research Program at Dana Farber/Partners Cancer Care

11

1 reference

26 July 2017

Dana Farber-Harvard Cancer Care

12

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

26 July 2017

1 reference

26 July 2017

91

1 reference

26 July 2017

2

1 reference

26 July 2017

293-298

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900496-7

26 July 2017

1 reference

7 January 2021

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900496-7

7 January 2021

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900496-7

7 January 2021

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900496-7

7 January 2021

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900496-7

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900496-7

7 January 2021

Gemcitabine-cisplatin: a schedule finding study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900496-7

7 January 2021

Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900496-7

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900496-7

7 January 2021

Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900496-7

7 January 2021

Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900496-7

7 January 2021

Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900496-7

7 January 2021

Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900496-7

7 January 2021

A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900496-7

7 January 2021

Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900496-7

7 January 2021

Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900496-7

7 January 2021

The role of gemcitabine-based doublets in the management of ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900496-7

7 January 2021

Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182).

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900496-7

7 January 2021

10.1016/S0090-8258(03)00496-7

Identifiers

DOI

1 reference

26 July 2017

1 reference